Belgium Jean-Christophe Tellier became UCB’s CEO on January 1, 2015 only a few years joining the company in 2011. Before taking on the role Tellier held positions as executive VP of European Operations and later successfully led UCB’s BioBrands and Solutions division as executive VP as well. Tellier was trained…
Africa The projected growth of pharma sales in Africa up to 2022. The continent’s pharma market stands to grow at a CAGR of 5.9 percent between 2018 and 2022 to reach a total of over USD 25 billion. Made with Visme Infographic Maker Key markets within Africa for pharmaceutical sales…
Czech Republic Jiří Volf, GM of BB Pharma, explains his motivation behind starting an entrepreneurial journey, the company’s competitive advantage in the face of international and local players, their business strategy in the Czech market and the exciting plans for BB Pharma to expand beyond European frontiers. We are often approached…
UAE Mundipharma, through its model of independent associated companies, is aiming to take the lead in the Middle East, Turkey & Africa markets through its continuous commitment to improving peoples’ lives. Ashraf Allam, regional VP for the META region, discusses his journey of building Mundipharma’s strong footprint in the region and…
CEE Ingrid Šmerdová, General Manager of Adamed in the Czech Republic and Slovakia, shares her thoughts about the role their future product pipeline will have in continuing to build the company’s growth within the Czech generics market. Moreover, Šmerdová portrays Adamed’s family-oriented approach as a key differentiator within the pharmaceutical industry…
Hungary MD Pál Szamosújvari, Judit Jávor, Pál Szamosújvari Jr—Founder, R&D Director, and Director of Pharma Patent respectively—share their insights on the activities of the company, the importance of R&D, the challenges of smaller companies, its marketing strategy of its niche products, and its internationalization strategy. Can you introduce yourself and…
Czech Republic Ewopharma’s Jan Krejčí, Country Manager for the Czech affiliate for the last eight years, shares the achievements of the company in its two main business pillars, prescription drugs, and consumer healthcare, and the successful entry into the hospital segment through the challenging and rewarding journey launching Santhera’s orphan drug for…
USA In 2019 big pharma companies prioritised shareholder payouts and dividends, with the eight biggest US pharma companies topping $31 billion in stock buybacks and the same amount in dividends. Revenues were not necessarily consistent with dividend and buyback amounts, and some critics argue that payouts should be lessened in favour…
Webinar With the recent publication of Ten years on: Measuring the Return from Pharmaceutical Innovation 2019, PharmaBoardroom has teamed up with Deloitte to offer its readers an exclusive webinar on The Future of Biopharma. On 25th February 2020, join us to discuss the major trends that have impacted the biopharma industry over the past ten years, the…
Puerto Rico Puerto Rico had to rebuild itself – in many cases quite literally – after the devastation wrought by Hurricane Maria in 2017. However, despite the havoc that Maria brought to the island’s telecommunications, energy and water supply, the jewel in Puerto Rico’s crown – its pharmaceutical industry – remained largely…
Hungary Gergely Jánoki CEO of Medi-Radiopharma shares his insights on the activities of the company, the trends in the radiopharmaceutical industry while highlighting regulatory trends, the importance of quality, the driving factors behind the company’s success and his long-term vision of for the company. We grew more than 60 percent…
Pharma Legal Handbook A brief overview of the situation regarding biosimilars and biologics. Prepared in association with SAARPE Association, a leading law firm in Algeria, this is an extract from The Pharma Legal Handbook: Algeria, available to purchase here for USD 99. 1. Are biosimilar medicines considered the same as generic medicines…
See our Cookie Privacy Policy Here